HeinOnline is a subscription-based resource containing thousands of academic and legal journals from inception; complete coverage of government documents such as U.S. Statutes at Large, U.S. Code, Federal Register, Code of Federal Regulations, U.S. Reports, and much more. Documents are image-based, fully searchable PDFs with the authority of print combined with the accessibility of a user-friendly and powerful database. For more information, request a quote or trial for your organization below.
![handle is hein.congrecreports/crptxadif0001 and id is 1 raw text is: AUTHENTICATEO
U.S. GOVERNMENT
INFORMATION
Op
116TH CONGRESS REPORT
2d Session HOUSE OF REPRESENTATIVES 116-512
SAFEGUARDING THERAPEUTICS ACT
SEPTEMBER 17, 2020.-Committed to the Committee of the Whole House on the
State of the Union and ordered to be printed
Mr. PALLONE, from the Committee on Energy and Commerce,
submitted the following
REPORT
[To accompany H.R. 5663]
The Committee on Energy and Commerce, to whom was referred
the bill (H.R. 5663) to amend the Federal Food, Drug, and Cos-
metic Act to give authority to the Secretary of Health and Human
Services, acting through the Commissioner of Food and Drugs, to
destroy counterfeit devices, having considered the same, reports fa-
vorably thereon with an amendment and recommends that the bill
as amended do pass.
CONTENTS
Page
I. Purpose and Sum m ary ............................................................................... 2
II. Background and Need for the Legislation ............................................... . 3
III. Com m ittee H earings ................................................................................. 4
IV . Com m ittee Consideration ......................................................................... 4
V . C om m ittee V otes ....................................................................................... 5
V I. O versight Findings ...................................................................................... 5
VII. New Budget Authority, Entitlement Authority, and Tax Expenditures 5
VIII. Federal M andates Statem ent ................................................................... 5
IX. Statement of General Performance Goals and Objectives ...................... 5
X. Duplication of Federal Program s ............................................................... 6
X I. Com m ittee Cost E stim ate .......................................................................... 6
XII. Earmarks, Limited Tax Benefits, and Limited Tariff Benefits ............... 6
XIII. Advisory Com m ittee Statem ent ................................................................. 6
XIV. Applicability to Legislative Branch ........................................................... 6
XV. Section-by-Section Analysis of the Legislation ......................................... 6
XVI. Changes in Existing Law Made by the Bill, as Reported ........................ 7
The amendment is as follows:
Strike all after the enacting clause and insert the following:
SECTION 1. SHORT TITLE.
This Act may be cited as the Safeguarding Therapeutics Act.
99-006](ViewImageLocal?handle=hein.congrecreports/crptxadif0001&div=1&collection=&method=preview&ext=.png&size=3)